Amgen and Basel, Switzerland-based Novartis announced they have expanded their collaboration with the Banner Alzheimer’s Institute (BAI) to launch a new clinical trial in Alzheimer’s.
Shockwave Medical reported $35 million in new financing, an extension of the company’s previously announced $45 million Series C financing. New investor Fidelity Management & Research Company participated, along with certain funds and accounts advised by T. Rowe Price Associates, Inc., a returning investor.
The debate explores whether food taxation is an indispensable strategy to correct obesity trends, or whether there should be other ways of approaching the problem.
Antineoplastic or anticancer drugs, affect the process of cell division i.e. are antiproliferative. They damage the DNA and initiate apoptosis, preventing the development and spread of neoplastic cells. Commonly used antineoplastic drugs can be divided into the following six categories: alkylating agents, anti-metabolites, anticancerous, antibiaties, aminoglutethimide and others. Today, Ddu, the leading global pharmaceutical & medical device B2B online platform, shares China’s Import and Export Report of Antineoplastic Drugs with you. General situation of global market of antineoplastic drugs According to the IMS’s latest report, “Global Oncology Trends 2017” showed that in 2016 the global market sales of antineoplastic drugs were 89.6 billion USD and 85 billion USD in 2015. Over the past five years, the global market of antineoplastic drugs has grown at a compound annual growth rate (CAGR) of 8.7% and is expected to exceed 147 billion USD by 2021. As indicated on the chart, the United States, the European Union and Japan are still the driving ...
"Our study suggests that estrogen treatment after menopause protects the memory that is needed for short-term cognitive tasks from the effects of stress," said Alexandra Ycaza Herrera, the study's lead author and a researcher at the USC Leonard Davis School of Gerontology.
A vaccine combining centralized ancestral genes from four major influenza strains appears to provide broad protection against the dangerous ailment, according to new research by a team from the Nebraska Center for Virology.
Dicerna Pharmaceuticals and Boehringer Ingelheim today announced a research collaboration and license agreement to discover and develop novel RNAi therapeutics for the treatment of chronic liver diseases. Dicerna can get up to $201 million in upfront and success-based development and commercialization milestones for an undisclosed target.
AbbVie, a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. , announced that the U.S. Food and Drug Administration (FDA) has granted priority review for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, being investigated for the management of endometriosis with associated pain.
From an analysis of more than 2,000 tumors spanning 12 types of human cancer, scientists have identified 27 new genes that could stop the disease in its tracks.
Clinical development has historically been a laborious and expensive process that stretches across all therapeutic areas. It is driven by lengthy patient recruitment timelines, increasingly complex study designs, and high procedural costs. Depending on whose data you believe, getting a new drug to market can now cost upwards of $1 billion and take more than 10 years or research and development effort. Additionally, a complex and dynamic regulatory framework has made sponsors reluctant to introduce new technologies to facilitate the development process.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.